On July 2, 2025, the Department of Justice announced the renewal of the DOJ-HHS False Claims Act Working Group, reinvigorating a partnership first launched during the previous Trump administration to strengthen healthcare fraud enforcement through the False Claims Act. This follows on the heels of the Trump administration’s announcement of the Civil Rights Fraud Initiative, describing plans to use the FCA to target programs and policies that support DEI, covered by Mitchell Sandler here.
Working Group Structure and Leadership
The Working Group will be jointly led by HHS's General Counsel, the Chief Counsel to the HHS Office of Inspector General, and DOJ's Deputy Assistant Attorney General of the Commercial Litigation Branch. Membership includes leadership from the Centers for Medicare and Medicaid Services Center for Program Integrity and designees from U.S. Attorneys' Offices.
Key Enforcement Priorities
The Working Group has identified several priority enforcement areas:
Medicare Advantage
Drug, device, and biologics pricing, including arrangements involving discounts, rebates, service fees, formulary placement, and price reporting
Barriers to patient access, including violations of network adequacy requirements
Kickbacks related to drugs, devices, durable medical equipment, and other products paid for by federal healthcare programs
Materially defective medical devices impacting patient safety
Manipulation of electronic health records to drive inappropriate utilization of Medicare covered products and services
Enhanced Enforcement Capabilities
The Working Group plans to expedite ongoing investigations and identify new leads by "leveraging HHS resources through enhanced data mining and assessment of HHS and HHS-OIG report findings." The partnership will also coordinate decisions on whether HHS should implement payment suspensions or whether DOJ should move to dismiss qui tam complaints.
Financial Services Implications
While primarily focused on healthcare fraud, the Working Group's priorities create potential exposure for financial services companies in several areas:
Healthcare payment processing companies may face increased scrutiny if their systems process fraudulent claims
Medical device and pharmaceutical financing providers could face liability if they facilitate fraudulent pricing schemes or kickback arrangements
Healthcare fintech companies providing billing or administrative services may be subject to False Claims Act liability if their services facilitate fraudulent billing practices
Compliance Considerations
Financial services companies with healthcare-related business lines should consider:
Strengthening customer due diligence processes for healthcare clients, particularly in the Working Group's priority areas
Ensuring transaction monitoring systems can identify potentially fraudulent healthcare transactions
Reviewing internal compliance programs and whistleblower reporting mechanisms
Assessing self-disclosure policies and procedures
The DOJ announcement encourages whistleblowers to identify and report FCA violations involving priority enforcement areas, and it encourages healthcare companies to identify and self-report such violations. As such, robust internal compliance programs are more critical than ever.
Looking Forward
The renewed DOJ-HHS partnership, combined with enhanced data mining capabilities and clearly defined priority areas, suggests healthcare fraud enforcement will likely increase in both frequency and sophistication. Mitchell Sandler PLLC has extensive experience advising financial services companies on compliance and enforcement matters, including white collar defense and corporate investigations involving healthcare fraud. For questions about how the DOJ-HHS False Claims Act Working Group may affect your business, please contact our team.
Download a PDF of this article here.
About The Authors
SIGN UP FOR UPDATES
Never miss our news, insights or events.
FEATURED NEWS
Seth Waxman
Bree Murphy
Sean Hennessy
Chloé Dolsenhe